Correspondence 0001104659-25-005535 from Theriva Biologics, Inc. (TOVX)

Theriva Biologics, Inc.
Date: Jan. 23, 2025 · CIK: 0000894158 · Accession: 0001104659-25-005535

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-283722

Date

January 23, 2025

Author

Steven A. Shallcross

Form

CORRESP

Company

Theriva Biologics, Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Tamika Sheppard Registration Statement on Form S-1 Filed December 10, 2024, as amended File No: 333-283722

Re: Theriva Biologics, Inc.

Dear Ms. Sheppard:

Reference is made to our letter, filed as correspondence via EDGAR on January 21, 2025, in which Theriva Biologics, Inc. (the “Company”) requested the acceleration of the effective date of the above-referenced Registration Statement for Thursday, January 23, 2025, at 5:00 p.m. Eastern Time.

The Company no longer requesting that such Registration Statement be declared effective at this time, and the Company hereby formally withdraw its request for acceleration of the above referenced effective date.

Very truly yours,
THERIVA BIOLOGICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

January 23, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tamika Sheppard

    Re:
    Theriva Biologics, Inc.

Registration Statement on Form S-1

Filed December 10, 2024, as amended

File No: 333-283722

Dear Ms. Sheppard:

Reference is made to our letter, filed as correspondence via EDGAR
on January 21, 2025, in which Theriva Biologics, Inc. (the “Company”) requested the acceleration of the effective date
of the above-referenced Registration Statement for Thursday, January 23, 2025, at 5:00 p.m. Eastern Time.

The Company no longer requesting that such Registration Statement be
declared effective at this time, and the Company hereby formally withdraw its request for acceleration of the above referenced effective
date.

    Very truly yours,

    THERIVA BIOLOGICS, INC.

    By:
    /s/ Steven A. Shallcross

    Name:
    Steven A. Shallcross

    Title:
    Chief Executive Officer and Chief Financial Officer

cc: Leslie Marlow, Blank Rome LLP

SecProbe.io